Leukemia Therapy
In AML patients, pretransplant MRD status predicts auto-SCT outcome
Published in Blood Weekly, December 11th, 2003
In a recent study from Italy, "A total of 31 adult patients with AML entered in the EORTC/GIMEMA AML-10 trial who received autologous stem cell transplantation (ASCT) after induction and consolidation chemotherapy, were prospectively evaluated for minimal residual disease (MRD) by multidimensional flow cytometry (MFC)."
"Using a cutoff level of 3.5 x 10-4 leukemic cells pre-ASCT, 12 patients (39%) were stratified to MRD high-risk group and 19 (61%) into MRD low-risk group," explained A....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-12-11)
More Articles from Blood Weekly
- Stem-Cell Research
Endoglin-based method enables purification of long-term repopulating HSCs - Leukemia Therapy
Stem cell mobilization feasible with rHu-G-CSF alone for CML patients in IM-induced CCR - Stem-Cell Research
IL-7 receptor expression determines lymphoid cell fate - Stem-Cell Transplantation
Low-dose cidofovir effective against post-SCT adenovirus infection - AIDS Epidemiology
China's AIDS epidemic is reaching "frightening" levels, renowned expert says - Acute Myeloid Leukemia
Stem cell Siglec-5 expression may aid AML disease monitoring. - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
